The company said worldwide revenue for Q1 2024 grew 24% year-over-year on a reported basis to $921.0 million, compared with $741.5 million for Q1 2023. It said organic revenue growth was 25%.

1. 01

   The company said worldwide revenue for Q1 2024 grew 24% year-over-year on a reported basis to $921.0 million, compared with $741.5 million for Q1 2023. It said organic revenue growth was 25%.

2. 02

   Dexcom said GAAP operating income for Q1 2024 was $101.1 million, or 11.0% of revenue, up from $47.2 million for Q1 2023. GAAP net income was $146.4 million, or $0.36 per diluted share, and the income tax benefit was $13.9 million.

3. 03

   The company said GAAP gross profit for Q1 2024 was $561.9 million, or 61.0% of revenue, compared with 62.4% for Q1 2023. Non-GAAP operating income was $140.2 million, or 15.2% of reported revenue.

4. 04

   As of March 31, 2024, the company said it held $2.90 billion in cash, cash equivalents and marketable securities, and its revolving credit facility was undrawn. It set full-year revenue guidance of approximately $4.20 to 4.35 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.